Stocks · Healthcare · Biotechnology
Spruce Biosciences, Inc. SPRB
$45.71 +2.10% Close, Oct 2, 2026 · NASDAQ · Market cap $125.8M
Expensive vs sector
Next earnings report: Nov 9, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 301.0% in a year.
- Over the past year the stock returned +413.6%, ahead of the S&P 500 by 398.5 percentage points.
- The stock is 75% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 2%
- Revenue growth accelerationTop 46%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 25%
- Accruals (lower is better)Top 40%
- Interest coverBottom 24%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 8%
- Free-cash-flow yieldBottom 14%
- EBITDA / enterprise valueBottom 4%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 1%
- 6-month returnBottom 13%
- 1-year return vs S&P 500Top 2%
- Distance from 52-week highBottom 3%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 39%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 29%
- Upside to consensus price targetTop 20%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 42%
- Maximum drawdown, 3 yearsBottom 1%
- Beta vs S&P 500 (lower is better)Top 1%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -100.0% | -100.0% | → |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -100.0% | -100.0% | → | Bottom 2% |
| Return on invested capital | -50.5% | — | Bottom 25% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -8.5%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -26.6×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -94.59%
- Shareholder yield
- -94.59%
- Share count change, 1 year
- +301.0%
- Share count change, 3-year CAGR
- +66.5%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 12, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- -1.4%
- Average 2-day reaction, last 8
- -6.5%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $135.75
- Target vs current price
- +197.0%
- Analysts with a rating
- 11
- Share rating Buy or Strong Buy
- 64%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 12, 2026 | -15.4% | +1.4% | +13.9% | +20.1% | — |
| May 13, 2026 | -22.1% | +1.6% | -14.9% | -16.8% | -17.3% |
| Mar 9, 2026 | +25.6% | +11.2% | +7.5% | +12.8% | -11.8% |
| Nov 10, 2025 | +6.3% | -9.0% | -16.3% | -35.7% | -44.2% |
| Aug 15, 2025 | +80.6% | +3.0% | -2.9% | +41.7% | +1351.4% |
| May 6, 2025 | -27.7% | -1.3% | +0.0% | -9.6% | +52.8% |
| Apr 15, 2025 | -17712.1% | -58.0% | -58.6% | -79.0% | -71.6% |
| Nov 11, 2024 | -5748.1% | -0.5% | -8.4% | +0.6% | -24.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -$6.68 | -$5.79 | -15.4% | — |
| May 13, 2026 | -$8.94 | -$7.32 | -22.1% | — |
| Mar 9, 2026 | -$9.58 | -$12.87 | +25.6% | — |
| Nov 10, 2025 | -$14.58 | -$15.56 | +6.3% | — |
| Aug 15, 2025 | -$3.50 | -$18.00 | +80.6% | — |
| May 6, 2025 | -$24.00 | -$18.80 | -27.7% | — |
| Apr 15, 2025 | -$42.75 | -$0.24 | -17712.1% | $700,000 |
| Nov 11, 2024 | -$15.79 | -$0.27 | -5748.1% | $602,000 |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -34.00% | — | — | Bottom 14% |
| Earnings yield | -89.41% | — | — | Bottom 8% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- +2.1%
- 200-day average slope (20 days)
- -6.8%
- Distance from 50-day average
- -10.9%
- Distance from 200-day average
- -23.2%
- RSI (14)
- 36.0
- Relative volume
- 0.75×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 59.9%
- Volatility vs own 5-year history
- 29th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- -11.04
- Correlation with S&P 500
- -0.12
- Current drawdown from 1-year high
- -75.0%
- Maximum drawdown, 3 years
- -98.9%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Nov 27, 2020 | May 22, 2025 | -99.8% | 1125 days | Not yet recovered |
| Oct 29, 2020 | Nov 5, 2020 | -20.4% | 5 days | 6 days (Nov 13, 2020) |
| Oct 14, 2020 | Oct 16, 2020 | -13.8% | 2 days | 5 days (Oct 23, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $125.8M
- EPS, diluted (TTM)
- -$40.87
- Revenue (TTM)
- $0
- 52-week range
- $7.88 – $240.00
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $10.1M | $4.9M | $0 |
| Gross profit | $0 | $0 | $10.1M | $4.9M | $0 |
| Operating income | -$42.1M | -$47.3M | -$52.0M | -$56.2M | -$36.5M |
| Net income | -$42.3M | -$46.2M | -$47.9M | -$53.0M | -$39.0M |
| EPS (diluted) | -$68.25 | -$72.00 | -$93.00 | -$96.75 | -$50.83 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $602,000 | $697,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.7M | -$23.6M | -$14.0M | -$2.1M | -$8.2M | -$14.6M | -$12.3M | -$16.2M |
| EPS (diluted) | -$16.50 | -$43.50 | -$24.00 | -$3.41 | -$14.58 | -$10.67 | -$8.94 | -$6.68 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$35.9M | -$41.7M | -$33.3M | -$56.0M | -$33.3M |
| Capital expenditure | -$93,000 | -$8,000 | -$7,000 | $0 | $0 |
| Free cash flow | -$36.0M | -$41.7M | -$33.3M | -$56.0M | -$33.3M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $462,000 | -$201,000 | $53.6M | $246,000 | $50.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $96.3M
- Total assets
- $102.9M
- Total liabilities
- $19.1M
- Total debt
- $7.7M
- Net debt
- -$88.6M
- Shareholders’ equity
- $83.7M
As of Jun 30, 2026 (filed Aug 12, 2026).
Short interest
- Shares sold short
- 416,140
- Days to cover
- 3.33
- Change vs previous report
- -5.5%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Aug 5, 2025
- 1-for-75